The pharmaceutical industry—Trends, problems and achievements: Review

1988 ◽  
Vol 21 (5) ◽  
pp. 117
Author(s):  
Barrie G. James
Author(s):  
В.М. Безденежных ◽  
Н.М. Ярцева

Главной проблемой в учете нематериальных активов фармацевтических компаний является ограниченность возможностей учета затрат, которые могут быть капитализированы в стоимость научно-исследовательского актива. Это негативно сказывается на рентабельности их бизнеса и финансовой устойчивости компании как факторе обеспечения ее экономической безопасности. Одним из направлений снижения этих затрат является возможность в отчетности, составленной по международным стандартам, использовать более широкий спектр неосязаемого имущества, что дает российским фармацевтическим компаниям дополнительные конкурентные преимущества. The main problem of intangible assets accounting of pharmaceutical companies is the limited expenses scope which might be capitalized in costs of scientific research asset. This problem not only determines the company's strategy, but also leads to a number of difficulties in managing and developing enterprises, primarily in the financial sector, but also in assessing risks of determining strategic priorities and selecting current management methods. This has a negative influence on the business profitability and the financial stability of the company. The wider spectrum of intangible property which brings additional competitive advantages to pharmaceutical companies is disclosed in the IFRS reporting.


2016 ◽  
Vol 2 (4) ◽  
pp. 234-241
Author(s):  
Mohammed Al-Shakka ◽  
Ebtesam Abood ◽  
Adel Al-Dhubhany ◽  
Sami Abdo Radman Aldubai ◽  
Khaled Said ◽  
...  

Because of the almost-instant connection with the welfare and well-being of individuals, pharmaceutical industry stands prominently as a very important factor for the improvement and progress of a healthy productive nation. These days, pharmaceutical industry thrives as one of the largest and exponentially expanding global industries. Nonetheless, millions of people in low income developing countries, have to suffer from the fatal consequences of the inaccessibility and non-availability of essential drugs. This is also happening in Yemen, where the pharmaceutical manufacturers sector have to face up to many challenges. The Yemen Drug Company (YEDCO) was founded in 1964 by the Yemeni government as it collaborated with private investors. It was endorsed as a company with the expertise in the medicinal drug marketing. YEDCO started its work by taking in drugs from foreign companies and then locally marketing and distributing them. In 1982, YEDCO built the first medicinal factory for drugs in Sana’a. Since then, seven companies were set up to manufacture medicines in Yemen. The expanding population has led to the need to have more pharmaceutical products. It may be understandable that pharmaceutical manufacturer companies are also hit by the political crisis in the country. Inadequate amount of fuel and raw material as well as low security status were some of the underlying factors behind these ill-effects in Yemen. Imported drugs make up about nearly 90% % of the pharmaceutical market compared to 10% drugs from the domestic market. This situation has led to an additional burden being shouldered by the national economy, where Yemen spends about US$263 million annually on pharmaceutical drugs, in reference to the national Supreme Drugs Authority. Although there is a very quick growth in the population and drugs consumption, the pharmaceutical industry has not been very active, where global pharmaceutical products play their role dominantly on the domestic market. The pharmaceutical production necessitates skilled human resources like university graduates. By contrast, the government and the private sector should also motivate the pharmaceutical industry and make use of the local employment


2011 ◽  
Vol 152 (47) ◽  
pp. 1894-1902
Author(s):  
János Antal ◽  
Attila Timár

Translational medicine is the emerging scientific discipline of the last decade which will set the benchmark for the pharmaceutical industry research and development, integrates inputs from the basic sciences of computer modeling and laboratory research through the pre-clinical and clinical phases of human research to the assimilation of new therapies and treatments into everyday practice of patient care and prevention. With this brief insight authors tried in their humble way to summarize the underlying basis, the present and the potential future of this emerging view, to draw attention to some of the challenges and tasks it faces and to highlight some of the promising approaches, trends and model developments and applications. Orv. Hetil., 2011, 152, 1894–1902.


Sign in / Sign up

Export Citation Format

Share Document